Retatrutide and Bupropion: Interaction Evidence Record

At a glance

• Review question / Is there FDA-reviewed or study-specific interaction evidence for retatrutide and Bupropion?
• Best evidence / registry searches and trial reports
• Evidence snapshot / 2026-08-09
• Commercial status / no FDA-approved product or ordinary retail supply
• HealthRX role / independent educational review; no retatrutide product or treatment offer

Direct answer

The answer is limited. Bupropion is an antidepressant used for several indications. The specifically named pharmacokinetic records in the 2026-08-09 snapshot involved midazolam, warfarin, caffeine, and metoprolol—not Bupropion. Absence of a dedicated named record is an evidence gap; it is not proof of compatibility or incompatibility.

The wording here is deliberately evidence-specific. “A study exists,” “a registry lists a site,” and “a paper reports an endpoint” are different statements from “a product is approved,” “a treatment works,” or “a person should use it.” This page makes only the first type of statement and links the controlling source.

Evidence map for Bupropion interaction evidence

How HealthRX evaluated this question

Interaction evidence has levels. A named pharmacokinetic study can measure exposure under controlled conditions; a clinical outcomes study can examine events in a defined population; an FDA label can synthesize reviewed evidence into instructions. Background use, anecdotes, and mechanism-based reasoning sit below those sources and should not be presented as settled guidance.

For this page, HealthRX asked: (1) Is bupropion interaction evidence named in the protocol or publication? (2) Was it a prespecified endpoint, eligibility factor, subgroup, or only background context? (3) Is the record complete, current, and peer reviewed? (4) Does an FDA action or approved label exist? That sequence prevents a research observation from being rewritten as a product claim.

Evidence checks specific to this record

Protocol provenance

Verify that the question is present in the dated protocol or analysis plan rather than introduced only after results were known. For bupropion interaction evidence, note whether the item is a primary endpoint, secondary endpoint, exploratory analysis, eligibility factor, or incidental mention. Those roles carry different evidentiary weight.

Exposure context

Document formulation, assigned regimen, treatment duration, background care, and protocol monitoring. Evidence about bupropion interaction evidence belongs to that controlled exposure context; it should not be generalized to an unverified product or to use outside a registered study.

Terminology discipline

Keep 'investigational,' 'registered,' 'completed,' 'published,' 'expanded access,' and 'FDA-approved' distinct. For bupropion interaction evidence, these terms describe different stages or pathways and should never be collapsed into the idea that a commercial treatment is available.

Missing-data handling

Check participant flow, discontinuations, missing measurements, and the estimand used for analysis. For bupropion interaction evidence, a result based only on completers may answer a different question from an analysis that accounts for everyone randomized.

Registry-to-publication match

Match the publication to its registry identifier, enrolled population, protocol version, and prespecified outcomes. If bupropion interaction evidence appears in a paper but not in the registered plan, readers should determine whether it was added, redefined, or reported as an exploratory analysis.

What remains unresolved

Retatrutide has no FDA-approved prescribing information or FDA-reviewed interaction table. Mechanism-based guesses, class analogies, anecdotes, and use of Bupropion as background therapy cannot establish whether concurrent use is safe, unsafe, beneficial, or appropriate.

The source hierarchy also matters. An FDA action controls approval status. ClinicalTrials.gov controls the public registry record. A peer-reviewed report can describe study methods and observations. A press release, seller page, social post, search result, or anecdote cannot replace those sources.

What evidence could change the answer

The strongest future evidence would be a registered study naming Bupropion, prespecifying pharmacokinetic or clinical endpoints, documenting exposure and timing, and publishing complete results.

Any new result should be read with its protocol and statistical analysis plan. Important checks include enrollment, prespecified outcomes, follow-up duration, missing-data handling, multiplicity, participant flow, sponsor involvement, and whether the finding has undergone peer review and regulatory review.

Current federal and commercial status

Retatrutide remains investigational. No retatrutide product is FDA-approved for any indication or available through ordinary commercial prescription or retail sale. FDA states that retatrutide cannot be used in compounding under federal law. HealthRX does not offer it. FDA's current statement says retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under federal law. A ClinicalTrials.gov study or eligibility-limited expanded-access record is not commercial approval, ordinary prescribing, retail availability, or evidence that HealthRX offers the investigational substance.

Federal regulation distinguishes scientific exchange from promotion: it does not restrict full exchange of scientific information, but it does restrict representing an investigational drug as safe or effective in a promotional context and precludes commercialization before approval.

Source selection and review method

HealthRX reviewed primary or primary-index sources current to 2026-08-09: ClinicalTrials.gov pharmacokinetic record NCT05445232; Rosenstock et al., phase 2 type 2 diabetes trial report; Jastreboff et al., phase 2 obesity trial report; FDA status statement for unapproved GLP-1 drugs; 21 CFR 312.7, Promotion of investigational drugs. Sources were selected because they control regulatory status, register a study, or index a peer-reviewed clinical report. The review reports study design and evidence limits without reproducing promotional outcome claims or converting protocols into patient instructions.

Frequently asked questions

›Is there an FDA-reviewed interaction table for Bupropion?

No. Retatrutide has no FDA-approved prescribing information and therefore no FDA-reviewed public interaction table.

›Does no dedicated study mean there is no interaction?

No. Absence of a named study is an evidence gap, not proof that concurrent use is compatible or incompatible.

›What source would answer the question best?

A registered study that names the substance, prespecifies pharmacokinetic or clinical endpoints, and publishes complete results would be more informative. FDA-reviewed labeling would be needed for public-use instructions.

References

1. ClinicalTrials.gov. Retatrutide pharmacokinetic interaction-study record. 2026. https://clinicaltrials.gov/study/NCT05445232
2. Rosenstock J, Frias J, Jastreboff AM, et al. Phase 2 retatrutide type 2 diabetes trial report. The Lancet. 2023. https://pubmed.ncbi.nlm.nih.gov/37385280/
3. Jastreboff AM, Kaplan LM, Frias JP, et al. Phase 2 retatrutide obesity trial report. New England Journal of Medicine. 2023. https://pubmed.ncbi.nlm.nih.gov/37366315/
4. U.S. Food and Drug Administration. FDA status statement for unapproved GLP-1 drugs. 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
5. Electronic Code of Federal Regulations. 21 CFR 312.7, Promotion of investigational drugs. 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-A/section-312.7